- This event has passed.
FULLY BOOKED: BioBriefing – Hot or Not : Trends for 2017
February 2, 2017 @ 4:00 pm - 5:30 pm AEDT
Event Navigation
This event is fully booked
What lies ahead for Melbourne’s biotechnology, medical technology and pharmaceutical industry in 2017? Our annual Hot or Not panel discussion will explore the global trends for the coming year with 5 speakers each presenting a short snap shot of what is HOT and what is NOT going into 2017 in their area of expertise.
Hear about:
- Shifts in international financial markets
- Trends in the intellectual property landscape
- Emerging technologies for cancer immunotherapy
- Challenges ahead for pharmaceutical manufacturing
- The role of big data in the continuing convergence of health and IT.
This event has been fully subscribed each year so we advise booking early to join us for this engaging Q&A panel discussion.
Speakers:
Dr Debra Yin Foo, Partner, Phillips Ormonde Fitzpatrick
Jonathan Ayres, Head of Premium Banking & Business Growth, Bank of Melbourne
Dr Ryan Cross, Postdoctoral Researcher, Jenkins Laboratory, Immunology Division, Walter and Eliza Hall Institute of Medical Research
Alison Hardacre, Managing Director, HealthKit
Alison Mew, Director, Centre for Biopharmaceutical Excellence (CBE)
Costs:
Members: $65
Non-Members: $130
(Prices include GST)
To check if your organisation is a member, click here
Sponsored by:
About Phillips Ormonde Fitzpatrick
Phillips Ormonde Fitzpatrick (POF) is a specialist IP firm that offers a comprehensive range of services from conception to enforcement. Our mission is to identify, protect, manage and enforce your IP assets, creating an IP strategy that is in line with your commercial objectives.
POF’s Chemistry and Life Sciences team comprises patent attorneys with the qualifications and experience to effectively safeguard your IP in all areas of chemistry, biotechnology and the life sciences in general. The team has extensive post-graduate research experience at some of the world’s leading institutions including Harvard University, Stanford University, Australian National University and the CSIRO.
Speaker Bios:
Dr Debra Yin Foo, Partner, Phillips Ormonde Fitzpatrick
Debra has over 27 years’ experience in patents and trade marks. Her practice includes advising clients in the biotechnology, pharmaceutical, chemical and medical industries concentrating on management, protection and enforcement of intellectual property rights. This includes drafting of applications, prosecution and all aspects of litigation ensuring adequate protection for the client.
Following her graduation majoring in chemistry and biochemistry, Debra completed an Honours degree exploring the immunology of parasites, including onchocerciasis infections. She then joined the Departments of Virology and Nutrition in the Tropical Veterinary Science Department at James Cook University.
Debra completed her PhD in Biochemistry after working on oxygen radical generation in immune cells in the presence of organochlorine pesticides where she conducted research to identify the reactive cells and the mechanisms of oxygen radical generation in those cells. She completed a Post Doctoral Fellowship in 1989 in Lausanne, Switzerland at the Swiss Institute for Experimental Cancer Research, focussing on molecular mechanisms in cancer cells and explored the use of antisense in cancer therapeutics.
Debra’s current clients include universities, research institutes actively involved in cancer and stem cell research, as well as small biotech companies. She specialises in biochemistry, cell biology, stem cell biology, immunology, oncology, cell therapeutics, diagnostics, biomarkers, microbiology and cell culture technologies.
Following her graduation majoring in chemistry and biochemistry, Debra completed an Honours degree exploring the immunology of parasites, including onchocerciasis infections. She then joined the Departments of Virology and Nutrition in the Tropical Veterinary Science Department at James Cook University.
Debra completed her PhD in Biochemistry after working on oxygen radical generation in immune cells in the presence of organochlorine pesticides where she conducted research to identify the reactive cells and the mechanisms of oxygen radical generation in those cells. She completed a Post Doctoral Fellowship in 1989 in Lausanne, Switzerland at the Swiss Institute for Experimental Cancer Research, focussing on molecular mechanisms in cancer cells and explored the use of antisense in cancer therapeutics.
Debra’s current clients include universities, research institutes actively involved in cancer and stem cell research, as well as small biotech companies. She specialises in biochemistry, cell biology, stem cell biology, immunology, oncology, cell therapeutics, diagnostics, biomarkers, microbiology and cell culture technologies.
Jonathan Ayres, Head of Premium Banking & Business Growth, Bank of Melbourne
Jonathan joined Bank of Melbourne in October of 2011 as the inaugural Head of Bank of Melbourne Private and spent 4 1/2 years in this role building the private banking business before taking on the role of Head of Premium Banking & Business Growth.
• Jonathan's role is to lead a team of senior professionals to deliver sustainable and targeted growth opportunities to all of Bank of Melbourne through Stratus, strategic alliances and partnerships, and Asian and migrant customer segments
• Prior to Bank of Melbourne, Jonathan spent 11 years at NAB in senior executive roles including Asset Management, Planning & Investments and NAB Private
• Jonathan holds a Bachelor of Business from Latrobe University and sits on the Regional Steering Council for International Cycling Executives
• Jonathan is a proud father to Thomas, Zara and Alexander, and partner to Amanda, avid cyclist, passionate urbanist, seeker of fine food and imbiber of fine wines, keen camper and international traveller and Carlton tragic.
• Jonathan's role is to lead a team of senior professionals to deliver sustainable and targeted growth opportunities to all of Bank of Melbourne through Stratus, strategic alliances and partnerships, and Asian and migrant customer segments
• Prior to Bank of Melbourne, Jonathan spent 11 years at NAB in senior executive roles including Asset Management, Planning & Investments and NAB Private
• Jonathan holds a Bachelor of Business from Latrobe University and sits on the Regional Steering Council for International Cycling Executives
• Jonathan is a proud father to Thomas, Zara and Alexander, and partner to Amanda, avid cyclist, passionate urbanist, seeker of fine food and imbiber of fine wines, keen camper and international traveller and Carlton tragic.
Dr Ryan Cross, Postdoctoral Researcher, Jenkins Laboratory, Immunology Division, Walter and Eliza Hall Institute of Medical Research
Ryan is an early career researcher with a focus on the pre-clinical development of novel immunotherapy strategies for the treatment of cancer. Research from his PhD on a DNA vaccine targeting the transcription factor MYB in colorectal cancer has led to the initiation of a Stage I clinical trial to begin recruitment in 2017 at Peter MacCallum Cancer Center.
Since completing his PhD in 2014 he has worked on the creation and pre-clinical development of chimeric antigen receptors (CAR) for use in the treatment of solid cancers. CAR T cells are quickly becoming a hot area of biotechnology having shown unprecedented success in the treatment of relapse refractory Acute Lymphoblastic Leukemia targeting the cell surface protein CD19.
In 2016 Ryan joined the laboratory of Dr Misty Jenkins at WEHI to work on the creation and refinement of novel CAR T cell therapies. In 2016 he was awarded a Jack Brockhoff Foundation Early Career Research Grant to create a CAR for the treatment of paediatric brain cancer.
Since completing his PhD in 2014 he has worked on the creation and pre-clinical development of chimeric antigen receptors (CAR) for use in the treatment of solid cancers. CAR T cells are quickly becoming a hot area of biotechnology having shown unprecedented success in the treatment of relapse refractory Acute Lymphoblastic Leukemia targeting the cell surface protein CD19.
In 2016 Ryan joined the laboratory of Dr Misty Jenkins at WEHI to work on the creation and refinement of novel CAR T cell therapies. In 2016 he was awarded a Jack Brockhoff Foundation Early Career Research Grant to create a CAR for the treatment of paediatric brain cancer.
Alison Hardacre, Managing Director, HealthKit
Alison is a global health technology entrepreneur. In 2016, Alison was named one of the Top 50 Australian and New Zealand Women in Tech, and in 2015 received the Victorian Pearcey Entrepreneur Award.
Alison also co-founded HealthKit, a technology platform that integrates practice and patient management software and consumer/patient services including searchable directories and personal health records. By bringing services together, HealthKit makes healthcare efficient, effective and accessible in Australia and internationally.
Before HealthKit, Alison was an accomplished general manager in health and banking, and a director of numerous health organisations. She speaks five Asian languages and holds an MBA from Melbourne Business School, and Law and Arts degrees from Monash University.
Alison also co-founded HealthKit, a technology platform that integrates practice and patient management software and consumer/patient services including searchable directories and personal health records. By bringing services together, HealthKit makes healthcare efficient, effective and accessible in Australia and internationally.
Before HealthKit, Alison was an accomplished general manager in health and banking, and a director of numerous health organisations. She speaks five Asian languages and holds an MBA from Melbourne Business School, and Law and Arts degrees from Monash University.
Alison Mew, Director, Centre for Biopharmaceutical Excellence (CBE)
Alison has more than 30 years experience in the Biopharmaceutical and Diagnostics industry, in Operations and General Management roles – both in Australia and internationally. Her corporate experience includes 13 years with CSL Ltd in senior executive positions across the Animal Health, Biosciences and Pharmaceutical Divisions – managing veterinary and human vaccines, antivenoms, diagnostics and other biologicals manufacture..
Alison spent three years providing consulting services in technical, operational and strategic management areas to both Australian and international organisations. In 2009, she joined Genetic Technologies Ltd as Chief Operating Officer where she was responsible for the genetic testing laboratories and was instrumental in the due diligence and acquisition of a new breast cancer risk assessment test (BREVAGen). This test was subsequently launched onto the US market in 2011, following significant validation and US regulatory submissions (CMS/CLIA) and Alison assumed responsibility for the reimbursement program. In December 2012, she was appointed CEO of Genetic Technologies and retained this role until December 2014.
Alison has served as Director for a number of subsidiaries of Genetic Technologies Ltd.
Alison spent three years providing consulting services in technical, operational and strategic management areas to both Australian and international organisations. In 2009, she joined Genetic Technologies Ltd as Chief Operating Officer where she was responsible for the genetic testing laboratories and was instrumental in the due diligence and acquisition of a new breast cancer risk assessment test (BREVAGen). This test was subsequently launched onto the US market in 2011, following significant validation and US regulatory submissions (CMS/CLIA) and Alison assumed responsibility for the reimbursement program. In December 2012, she was appointed CEO of Genetic Technologies and retained this role until December 2014.
Alison has served as Director for a number of subsidiaries of Genetic Technologies Ltd.
